Coeptis Therapeutics (NASDAQ:ZSQR) Sees Strong Trading Volume – Time to Buy?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shares saw unusually-strong trading volume on Tuesday . Approximately 58,682 shares changed hands during trading, a decline of 45% from the previous session’s volume of 107,489 shares.The stock last traded at $13.32 and had previously closed at $12.77.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Coeptis Therapeutics Stock Up 8.1%

The firm’s 50 day moving average price is $11.90 and its two-hundred day moving average price is $12.90. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $709.73 million, a price-to-earnings ratio of -5.48 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Institutional Trading of Coeptis Therapeutics

A number of hedge funds have recently modified their holdings of ZSQR. Steward Partners Investment Advisory LLC lifted its stake in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics during the 3rd quarter worth about $140,000. Marshall Wace LLP acquired a new stake in shares of Coeptis Therapeutics during the 4th quarter worth about $259,000. State Street Corp raised its stake in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares in the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.